Experimental drug: Ondansetron — Competitive Intelligence Brief

Experimental drug: Ondansetron (Experimental drug: Ondansetron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology, Gastroenterology, Anesthesia.

phase 3 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology, Anesthesia Small molecule

Target snapshot

Experimental drug: Ondansetron (Experimental drug: Ondansetron) — CCTU. Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Experimental drug: Ondansetron TARGET	Experimental drug: Ondansetron	CCTU	phase 3	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Palonosetron only	Palonosetron only	NYU Langone Health	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Dexamethasone + Ondansetron	Dexamethasone + Ondansetron	University of Catania	marketed	Corticosteroid + 5-HT3 antagonist combination	Glucocorticoid receptor; 5-HT3 receptor
ondansetron and dyclonine hydrochloride	ondansetron and dyclonine hydrochloride	Peking Union Medical College Hospital	marketed	5-HT3 receptor antagonist with local anesthetic	5-HT3 receptor; local anesthetic (sodium channel blockade)
Ramosetron, Aprepitant, Dexamethasone	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

1. Helsinn Healthcare SA · 4 drugs in this class
2. LG Life Sciences · 3 drugs in this class
3. University of Malaya · 2 drugs in this class
4. GlaxoSmithKline · 1 drug in this class
5. Hamad Medical Corporation · 1 drug in this class
6. Eye & ENT Hospital of Fudan University · 1 drug in this class
7. Instituto Mexicano del Seguro Social · 1 drug in this class
8. Chongqing University Cancer Hospital · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class
10. MonoSol Rx · 1 drug in this class